Regulatory T cell (Treg) is one of the major immunosuppressors in 2 tumor-bearing hosts. Although Treg-depletion therapy has been shown to induce a complete cure of tumor-bearing mice, this is not always successful treatment.
Introduction
The accumulative evidence indicates that it is important to consider two immunological aspects for developing an efficient tumor immunotherapy. First, immunological help, such as an efficient adjuvant provoking type 1 immunity, should be introduced into tumor bearers for inducing and maintaining tumor-specific CTLs (1) . Secondly, immunosupressions in tumor bearers should be removed to induce fully activation of tumor-specific CTLs (1) (2) (3) (4) (5) . Several immunosuppressive mechanisms in tumor bearers have evaluated in animal experiments (2, 3, (5) (6) (7) (8) (9) (10) . However, the evaluated mechanisms in mice were not always applicable to clinical study (11, 12) . The difficulties are because (i) many investigators used long-term cultured mouse tumor-cell lines, possessing distinct properties from primary tumors; (ii) most primary mouse tumors used for experiments are MCA-induced sarcoma even though over 98% of human cancer consisted of carcinoma, because it has been difficult to establish MCA-induced carcinomas. Therefore, it is necessary to use primary mouse carcinoma to define their immunosuppressive tumor escape mechanisms, which might provide some light for evaluating the mechanisms underlying human carcinoma-induced immunosuppression.
In previous work (13), we have first established a novel carcinogenesis model to induce both squamous cell carcinoma (SCC) and fibrosarcoma by a single intradermally (i.d) injection of MCA. Using this method, we could easily and shortly obtain two different types of primary tumors, SCC and sarcoma.
Thus, now, it becomes possible to investigate the distinct immunosuppressive mechanisms between primary-induced carcinoma and sarcoma.
Treg-mediated immunosupression is one of the major obstacles to cure tumors by immunotherapy (2, 5, 6, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Many investigators have tried to attenuate Treg-mediated immunosuppression by targeting therapy using Treg-associated molecules such as CD25, CTLA-4, GITR, TGF-β, FR4, OX40
and TLR8 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . Although Treg-depletion therapy by injecting anti-CD25 mAb is a major strategy to remove Treg-mediated immunosupression, this method did not always successful in inducing tumor rejection (15, 16, 27, 28) . However, it remains poorly understood why some tumors were refractory to Treg-depletion therapy and escaped from host anti-tumor defense mechanisms.
Here, we initially demonstrated that MCA-induced primary carcinomas were refractory to Treg-depletion therapy, while MCA-induced primary sarcomas were sensitive to it. This is because Tregs were rapidly recovered in carcinoma-bearing mice by active TGF-β, which was highly produced by carcinoma compared with sarcoma. Based on these findings, we demonstrated that combination treatment of SCC-bearing mice with anti-CD25 mAb and anti-TGF-β mAb caused a complete cure of tumor-bearing mice via blocking the rapid recovery of Tregs. Thus, our paper initially indicated that there is a distinct regulation of Treg-mediated immunosuppressive tumor escape between carcinoma and sarcoma.
Materials and Methods
Mice and tumor cell line. BALB/c mice were obtained from Charles River Japan (Yokohama, Japan). All mice were female and were used at 6-8 weeks of age.
Squamous cell carcinomas (SCCs) and fibrosarcomas were obtained as described in previous paper (13) . In brief, we injected 500µg of MCA intradermally. When the tumor reached >100 mm 3 , we minced the tumor and seeded to 10cm dish. The cells were subcultured when they became confluent.
We characterized cytokeratin-positive CMC-1 and CMC-9 as SCC, and vimentic-positive CMS-G2 and CMS-G4 as sarcoma by immunohistochmistry (13) . We cultured SCCs and sarcomas in RPMI medium (1640, Sigma-Aldrich, Japan) containing 10% FCS (Nichirei Bioscience, Tokyo, Japan) and used within 10th passage. Mv1Lu cell (mink lung epithelial cell line) was donated by Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer (Tohoku University, Japan) and were cultured in MEME medium (M4655, Sigma-Aldrich, Japan) containing 10% FCS.
Reagents. Anti-Foxp3 polyclonal Ab for immunochemical staining was kindly donated by Dr. K Matsushima (Tokyo University, Japan) (29) . Anti-Foxp3 mAb (150D/E4) used along with anti-Ki67 mAb and anti-Foxp3 mAb (FJK-16S) used along with anti-CD4 mAb were purchased from eBioscience (CA, USA).
FITC-CD4 mAb (GK1.5) was purchased from DB bioscience (Fukushima, Japan). Anti-Ki-67 mAb (TEC-3) was purchased from Dako Japan (Tokyo, Japan) and its control IgG mAb was purchased from DB bioscience. Anti-TGF-β mAb (1D11), its control IgG mAb (13C4), and anti-CD25 mAb (PC61) were purified by Kitayama Labes (Nagano, Japan), and the hybridomas were purchased from American Type Culture Collection (ATCC, VA, USA). Control IgG mAb of PC61 was purchased from DB bioscience. Recombinant human TGF-β1 (rhTGF-β) was purchased from PeproTech. rhIL-2 was kindly donated by T Yamada (SHIONOGI & CO., LTD. Osaka, Japan).
Immunochemical staining. Snap-frozen, Tissue-Tek-embedded lymph nodes were cut at 5-7µm, fixed for 10min in cold acetone and used for immunohistochemical analysis. We used an already established double-immunofluorescence staining protocol for Foxp3 and CD4 (29) . Briefly, the primary antibodies were diluted in 1% BSA (polyclonal rabbit antibody against murine Foxp3 at a concentration of 5 mg/mL and anti-CD4 mAb (diluted 1：500). The secondary antibody was applied at a 1：500 dilution (anti-rat IgG-Alexa 546, anti-rabbit IgG-Alexa 488; Alexa, Leiden, The Netherlands).
Finally, the samples were analyzed with Olympus FV500 confocal laser scanning microscope system (Olympus Optical, Tokyo, Japan).
4hr and the radioactivity incorporated in cells was measured as a representation of proliferation of the T cells.
Mv1Lu assay.
We detected the levels of active TGF-β in tumor supernatant (sup) by slightly modified method described in previous paper (30) . Concretely, Mv1Lu (5x10 (Fig.3A) . The similar results were also demonstrated in an immunohistochemical analysis (Fig.3B) . These results indicated that TGF-β plays a pivotal role for the induction of Tregs in SCC-bearing mice. Therefore, it was speculated that the augmented Treg induction in SCC-bearing mice might be due to their higher producing ability of active TGF-β compared with sarcoma. To demonstrate our working hypothesis, the producibility of active TGF-β from SCC and sarcoma were determined by Mv1Lu assay. Several kinds of primary SCC or sarcoma lines were cultured and TGF-β activity in their culture supernatants was measured as described in Materials and Methods. Interestingly, most SCC lines exhibited higher ability to produce active TGF-β than sarcoma lines (Fig. 3C) . These results indicated that higher ability to produce active TGF-β in MCA-induced carcinoma might explain why larger numbers of Tregs were increased in DLN of carcinoma-bearing hosts compared with sarcoma-bearers.
MCA-induced carcinoma is more resistant to anti-CD25 mAb treatment than sarcoma following a rapid recovery of Tregs.
In order to assess the immunosuppressive effects of Tregs on antitumor immunity in vivo, we depleted Tregs by the treatment with anti-CD25 mAb before inoculation of several SCC lines or sarcoma lines at 2x10 6 cells/mouse.
Surprisingly, the administration of anti-CD25 mAb showed no significant effect on the growth of SCCs, while it completely inhibited the growth of all sarcoma lines through the elimination of Treg-mediated immunosuppression (Fig. 4A, B) .
For analyzing the regulation of Tregs between both types of tumor-bearing mice, we selected representative SCC (CMC-1) and sarcoma (CMS-G4), which showed contrastive TGF-β production ( Fig.3D) suggested that SCC-derived TGF-β might accelerate the recovery of Tregs after the depletion, which might induce the refractoriness to anti-CD25 mAb treatment.
To examine the critical role of TGF-β for the rapid recovery of Tregs, we administered anti-TGF-β mAb (1D11) into CMC-1-bearing mice after the injection of anti-CD25 mAb (PC61). As shown in Table 1 As shown in Fig.4 , here, we initially find that there is a clear difference in the sensitivity against Treg-depletion therapy between primary SCC and sarcomas, which are induced by a single injection of MCA (13) . We consider that it is greatly valuable to evaluate the reason why mouse carcinomas are more refractory to
Treg-depletion therapy than sarcomas for developing an efficient strategy to human cancer, most of which are consists of carcinomas but not sarcomas.
In MCA-induced SCC-bearing mice, the number of Foxp3 + CD4 + T cells was increased in DLN, but neither spleen nor distal LN (Fig. 1) . In tumor site, foxp3 + T cells existed as shown in supplementary data Fig. S1 , but it was not easy to compare with LN and spleen simply because they were scattered in low density.
Since there was no different immunosuppressive ability among the Tregs of DLN, distal LN and spleen (supplementary Fig. S1 ), the number of Tregs might be essential for assessing the inhibition mediated by Tregs. In previous paper (33, 34) , we demonstrated that tumor-vaccination combined with CpG adjuvant or Th1 cells caused a great accumulation of tumor-specific CTL in DLN but not distal LN and spleen. Therefore, not only positive, but also negative immunoregulatory cells appears to be activated at DLN of tumor-bearing mice.
Indeed, we confirmed that Tregs were actively divided in DLN by Ki-67 stainig (Data not shown). Thus, the vigorous increase of Tregs in DLN of tumor-bearing mice may be rational for supporting tumor escape from antitumor immunity. The great increase of Tregs in DLN of SCC-bearing mice, but not sarcoma-bearing mice (Fig.2) , indicating that SCCs exhibit stronger immunosuppressive activity than sarcoma via their profound Treg-induction.
The numbers of Tregs in DLN of SCC-bearing mice were higher than those of sarcoma-bearing mice even when the mice were treated with anti-CD25 mAb to deplete Tregs before inoculation of tumors (Fig.5) . Moreover, Treg-depletion therapy induces the rejection of sarcomas but not SSCs (Fig.4) . Judging from these results, we hypothesized that TGF-β higher produced by SCC than sarcoma may be influence on a rapid recovery of Tregs during tumor growing in Treg-depleted mice. As expected, it was demonstrated that the refractoriness of SCC-bearing mice were overcomed by combination treatment with anti-TGF-β mAb administration in addition to anti-CD25 mAb（Fig.6）. By this combination treatment, the replenishment of Tregs was blocked, resulting in a complete cure of mice from SCC, which was refractory to anti-CD25 mAb treatment alone (Table 1 and Fig.6 ). Although we succeeded in the complete rejection of high highly TGF-β-producing CMC-1 by combination therapy of anti-CD25 mAb and anti-TGF-β mAb, it remains to be addressed whether the same strategy might be applicable to other carcinomas.
In this paper, we demonstrated that TGF-β-producing SCC were resistant to Treg-depletion therapy because of rapid Treg recovery mediated by TGF-β derived from SCC (Fig. 4-7) . However, despite the result that some sarcoma lines produced the same level of TGF-β as carcinomas (Fig. 3C) 
